Profusa, Inc. (PFSA): Entry into a Material Definitive Agreement
Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ea030001701ex2-1.htm OPTION AGREEMENT, DATED JULY 31, 2026, BY AND AMONG PROFUSA, INC Exhibit 2.1 OPTION AGREEMENT This Option Agreement (this “ Agreement ”) is made and entered into as of July 31, 2026, by and among Profusa, Inc., a Delaware corporation (the “ Buyer ”),
How this was made
The 30-second read
Why it matters
If exercised, Profusa would acquire 100% of G3 and substantially all of Med Screen through a closing that issues Profusa Series A non-voting convertible preferred and common stock as consideration, with timing tied to delivery of specified audited and reviewed financial information.
Market read
This is a primary corporate development disclosure that can re-rate the stock on deal optionality, but the excerpt suggests execution risk and potential dilution until financing and economics are confirmed.
What to watch
Key deal economics and financing terms are not shown in the excerpt; traders should verify the option exercise shares, any caps/termination rights, and whether equity financing is committed.
Background
The 8-K reports entry into a material definitive agreement, specifically an option agreement, plus unregistered sales of equity securities.
Ticker impact
Profusa entered a material definitive option agreement giving it the right to buy 100% of G3 and substantially all of Med Screen, via option exercise tied to audited 2024-2025 and interim 2026 financials.
Potentially supportive for deal optionality, but dilution/financing uncertainty and long-dated conditions can limit near-term upside.
An 8-K Item 1.01 is a primary disclosure of deal structure and timing conditions, but the excerpt does not include economics (strike price/valuation) or whether financing is secured, which tempers conviction.
Market effects
Signals continued consolidation in diagnostics/healthcare services via equity-structured acquisition options.
No clear regional read-through beyond US-based target entities.
Limited global impact; primarily a US small-cap corporate development.
Counterpoint
The option structure and long conditions (audited 2024-2025 and reviewed 2026 quarters) may delay certainty, so the market may discount it as low-probability or dilution-heavy.
Key entities
- issuerProfusa, Inc.
Buyer under the option agreement, filing the 8-K (PFSA).
- target companyG3 Vision Labs Inc.
Target company whose equity is 100% owned by sellers and is part of the acquisition option.
- target companyAcutis Diagnostics Inc.
Target company owned by G3 and included in the option agreement structure.
- target companyDominion Diagnostics LLC
Target company owned by G3 and included in the option agreement structure.
- target companyMed Screen Laboratories Inc.
Target company where sellers hold substantially all of the equity, included in the option agreement.
